ARQT
Arcutis Biotherapeutics, Inc.
Price Chart
Latest Quote
$24.59
+1.36 (+5.85%)
Current Price
| Previous Close | $23.23 |
| Open | $23.20 |
| Day High | $25.34 |
| Day Low | $22.95 |
| Volume | 2,696,353 |
Stock Information
| Shares Outstanding | 125.08M |
| Total Debt | $114.67M |
| Cash Equivalents | $224.00M |
| Revenue | $415.62M |
| Net Income | $-2.38M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.05B |
| EPS (TTM) | $-0.02 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.94B |
| Sales | $415.62M |
| Income | $-2.38M |
| Book/sh | $1.52 |
| Cash/sh | $1.79 |
| Employees | 354 |
Financial Ratios
| Quick Ratio | 2.26 |
| Current Ratio | 2.68 |
| Debt/Eq | 60.47 |
Returns & Margins
| ROA | 0.50% |
| ROE | -1.43% |
| Gross Margin | 90.94% |
| Operating Margin | -8.62% |
| Profit Margin | -0.57% |
Ownership
| Insider Ownership | 1.77% |
| Institutional Ownership | 110.21% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 21.10 |
| P/S | 7.34 |
| P/B | 16.07 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $34.62 |
Technical Indicators
| SMA20 | $21.58 |
| SMA50 | $22.59 |
| SMA200 | $23.79 |
| RSI | 76.11 |
| ATR | 0.9819 |
| Shares Float | 92.59M |
| Short Float | 13.84% |
| Short Ratio | 7.62 |
| Volatility | 1.52 |
| Rel Volume | 0.76 |
Performance History
| Week | +14.84% |
| Month | +12.40% |
| Quarter | +7.16% |
| 6 Months | -18.11% |
| YTD | -15.93% |
| Year | +77.57% |
| 3 Years | +153.17% |
| 5 Years | -12.37% |
| 10 Years | +11.83% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $24.38 | 1,328,300 |
| 2026-06-11 | $24.59 | 2,749,000 |
| 2026-06-10 | $23.23 | 1,412,400 |
| 2026-06-09 | $22.79 | 1,777,200 |
| 2026-06-08 | $21.54 | 1,120,800 |
| 2026-06-05 | $21.23 | 1,209,400 |
| 2026-06-04 | $21.95 | 1,173,400 |
| 2026-06-03 | $21.35 | 1,062,800 |
| 2026-06-02 | $20.79 | 2,311,600 |
| 2026-06-01 | $21.47 | 1,602,200 |
| 2026-05-29 | $21.46 | 1,629,700 |
| 2026-05-28 | $21.44 | 957,000 |
| 2026-05-27 | $21.15 | 1,504,200 |
| 2026-05-26 | $21.11 | 2,609,800 |
| 2026-05-22 | $20.86 | 1,163,000 |
| 2026-05-21 | $21.01 | 1,428,000 |
| 2026-05-20 | $20.47 | 2,325,900 |
| 2026-05-19 | $19.50 | 4,512,100 |
| 2026-05-18 | $20.03 | 1,412,100 |
| 2026-05-15 | $21.32 | 1,600,100 |
| 2026-05-14 | $21.57 | 1,865,500 |
| 2026-05-13 | $21.69 | 3,663,300 |
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
đ° Latest News
Is Arcutis (ARQT) Using Genital Psoriasis Education to Quietly Reshape Its Dermatology Strategy?
Simply Wall St. âĸ 2026-06-12T01:15:37Z
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status
MarketBeat âĸ 2026-06-10T00:02:51Z
Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE Expansion
Simply Wall St. âĸ 2026-05-09T05:19:31Z
Arcutis Biotherapeutics, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-07T12:30:00Z
Arcutis Biotherapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-06T22:59:43Z
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-06T21:25:03Z
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Zacks âĸ 2026-04-30T14:00:08Z
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
Zacks âĸ 2026-04-29T14:00:27Z
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Moves
Simply Wall St. âĸ 2026-04-24T00:16:05Z
How The Arcutis Biotherapeutics (ARQT) Narrative Is Shifting Around Zoryve And The $35 Target
Simply Wall St. âĸ 2026-04-23T18:05:34Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $36,695,000 | $19,128,000 | $4,987,000 | $754,000 |
| Cost Of Revenue | $36,695,000 | $19,128,000 | $4,987,000 | $754,000 |
| Total Revenue | $376,072,000 | $196,542,000 | $59,606,000 | $3,686,000 |
| Operating Revenue | $372,072,000 | $166,542,000 | $29,186,000 | $3,686,000 |
| Expenses | ||||
| Interest Expense | $12,083,000 | $27,168,000 | $29,712,000 | $15,652,000 |
| Total Expenses | $388,299,000 | $324,939,000 | $300,707,000 | $305,313,000 |
| Other Income Expense | $443,000 | $47,000 | $-731,000 | $5,821,000 |
| Other Non Operating Income Expenses | $443,000 | $47,000 | $-731,000 | $5,821,000 |
| Net Non Operating Interest Income Expense | $-3,186,000 | $-11,042,000 | $-17,195,000 | $-15,652,000 |
| Interest Expense Non Operating | $12,083,000 | $27,168,000 | $29,712,000 | $15,652,000 |
| Operating Expense | $351,604,000 | $305,811,000 | $295,720,000 | $304,559,000 |
| General And Administrative Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-16,141,000 | $-140,039,000 | $-262,140,000 | $-311,458,000 |
| Net Interest Income | $-3,186,000 | $-11,042,000 | $-17,195,000 | $-15,652,000 |
| Interest Income | $8,897,000 | $16,126,000 | $12,517,000 | - |
| Normalized Income | $-16,141,000 | $-140,039,000 | $-262,140,000 | $-311,458,000 |
| Net Income From Continuing And Discontinued Operation | $-16,141,000 | $-140,039,000 | $-262,140,000 | $-311,458,000 |
| Total Operating Income As Reported | $-12,227,000 | $-128,397,000 | $-241,101,000 | $-301,627,000 |
| Net Income Common Stockholders | $-16,141,000 | $-140,039,000 | $-262,140,000 | $-311,458,000 |
| Net Income | $-16,141,000 | $-140,039,000 | $-262,140,000 | $-311,458,000 |
| Net Income Including Noncontrolling Interests | $-16,141,000 | $-140,039,000 | $-262,140,000 | $-311,458,000 |
| Net Income Continuous Operations | $-16,141,000 | $-140,039,000 | $-262,140,000 | $-311,458,000 |
| Pretax Income | $-14,970,000 | $-139,392,000 | $-259,027,000 | $-311,458,000 |
| Interest Income Non Operating | $8,897,000 | $16,126,000 | $12,517,000 | - |
| Operating Income | $-12,227,000 | $-128,397,000 | $-241,101,000 | $-301,627,000 |
| Gross Profit | $339,377,000 | $177,414,000 | $54,619,000 | $2,932,000 |
| Per Share | ||||
| Diluted EPS | $-0.13 | $-1.16 | $-3.78 | $-5.66 |
| Basic EPS | $-0.13 | $-1.16 | $-3.78 | $-5.66 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $1,780,000 | $-110,265,000 | $-228,565,000 | $-294,872,000 |
| Reconciled Depreciation | $4,667,000 | $1,959,000 | $750,000 | $934,000 |
| EBITDA (Bullshit earnings) | $1,780,000 | $-110,265,000 | $-228,565,000 | $-294,872,000 |
| EBIT | $-2,887,000 | $-112,224,000 | $-229,315,000 | $-295,806,000 |
| Diluted Average Shares | $127,234,000 | $120,957,633 | $69,305,487 | $55,032,265 |
| Basic Average Shares | $127,234,000 | $120,957,633 | $69,305,487 | $55,032,265 |
| Diluted NI Availto Com Stockholders | $-16,141,000 | $-140,039,000 | $-262,140,000 | $-311,458,000 |
| Tax Provision | $1,171,000 | $647,000 | $3,113,000 | $0 |
| Research And Development | $77,051,000 | $76,420,000 | $110,575,000 | $182,435,000 |
| Selling General And Administration | $274,553,000 | $229,391,000 | $185,145,000 | $122,124,000 |
| Other Gand A | - | - | - | - |
Fetched: 2026-06-09
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $174,667,000 | $148,062,000 | $82,229,000 | $202,393,000 |
| Total Assets | $432,973,000 | $348,889,000 | $341,365,000 | $449,274,000 |
| Total Non Current Assets | $21,741,000 | $13,069,000 | $10,934,000 | $11,868,000 |
| Other Non Current Assets | $1,419,000 | $596,000 | $596,000 | $78,000 |
| Goodwill And Other Intangible Assets | $14,812,000 | $9,479,000 | $6,438,000 | $7,188,000 |
| Current Assets | $411,232,000 | $335,820,000 | $330,431,000 | $437,406,000 |
| Other Current Assets | $9,017,000 | $9,043,000 | $8,208,000 | $6,257,000 |
| Restricted Cash | $308,000 | $617,000 | $925,000 | $1,234,000 |
| Prepaid Assets | $12,062,000 | $10,613,000 | $10,496,000 | $4,354,000 |
| Inventory | $22,634,000 | $14,526,000 | $13,134,000 | $7,514,000 |
| Receivables | $146,229,000 | $73,066,000 | $25,807,000 | $8,458,000 |
| Accounts Receivable | $146,229,000 | $73,066,000 | $25,807,000 | $8,458,000 |
| Cash Cash Equivalents And Short Term Investments | $220,982,000 | $227,955,000 | $271,861,000 | $409,589,000 |
| Cash And Cash Equivalents | $42,907,000 | $71,335,000 | $88,398,000 | $53,641,000 |
| Cash Equivalents | $42,907,000 | $71,335,000 | $88,398,000 | $53,641,000 |
| Taxes Receivable | - | - | - | - |
| Debt | ||||
| Net Debt | $66,052,000 | $35,868,000 | $113,401,000 | $144,128,000 |
| Total Debt | $114,225,000 | $109,765,000 | $205,916,000 | $202,543,000 |
| Long Term Debt And Capital Lease Obligation | $113,225,000 | $109,765,000 | $205,181,000 | $201,886,000 |
| Long Term Debt | $107,959,000 | $107,203,000 | $201,799,000 | $197,769,000 |
| Current Debt And Capital Lease Obligation | $1,000,000 | $820,000 | $735,000 | $657,000 |
| Current Debt | $1,000,000 | - | - | - |
| Other Current Borrowings | $1,000,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $243,494,000 | $191,348,000 | $252,698,000 | $239,693,000 |
| Total Non Current Liabilities Net Minority Interest | $113,656,000 | $110,335,000 | $206,030,000 | $201,886,000 |
| Other Non Current Liabilities | $431,000 | $570,000 | $849,000 | - |
| Current Liabilities | $129,838,000 | $81,013,000 | $46,668,000 | $37,807,000 |
| Payables And Accrued Expenses | $108,305,000 | $60,266,000 | $31,061,000 | $23,150,000 |
| Payables | $12,528,000 | $14,220,000 | $11,992,000 | $8,827,000 |
| Accounts Payable | $12,528,000 | $14,220,000 | $11,992,000 | $8,827,000 |
| Equity | ||||
| Common Stock Equity | $189,479,000 | $157,541,000 | $88,667,000 | $209,581,000 |
| Total Equity Gross Minority Interest | $189,479,000 | $157,541,000 | $88,667,000 | $209,581,000 |
| Stockholders Equity | $189,479,000 | $157,541,000 | $88,667,000 | $209,581,000 |
| Gains Losses Not Affecting Retained Earnings | $-44,000 | $-7,000 | $4,000 | $-1,086,000 |
| Other Equity Adjustments | $-44,000 | $-7,000 | $4,000 | $-1,086,000 |
| Retained Earnings | $-1,138,084,000 | $-1,121,943,000 | $-981,904,000 | $-719,764,000 |
| Other | ||||
| Ordinary Shares Number | $123,332,672 | $117,848,033 | $96,787,343 | $61,036,787 |
| Share Issued | $123,332,672 | $117,848,033 | $96,787,343 | $61,036,787 |
| Tangible Book Value | $174,667,000 | $148,062,000 | $82,229,000 | $202,393,000 |
| Invested Capital | $298,438,000 | $264,744,000 | $290,466,000 | $407,350,000 |
| Working Capital | $281,394,000 | $254,807,000 | $283,763,000 | $399,599,000 |
| Capital Lease Obligations | $5,266,000 | $2,562,000 | $4,117,000 | $4,774,000 |
| Total Capitalization | $297,438,000 | $264,744,000 | $290,466,000 | $407,350,000 |
| Additional Paid In Capital | $1,327,595,000 | $1,279,479,000 | $1,070,558,000 | $930,425,000 |
| Capital Stock | $12,000 | $12,000 | $9,000 | $6,000 |
| Common Stock | $12,000 | $12,000 | $9,000 | $6,000 |
| Long Term Capital Lease Obligation | $5,266,000 | $2,562,000 | $3,382,000 | $4,117,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $20,533,000 | $20,747,000 | $14,872,000 | $14,000,000 |
| Current Accrued Expenses | $95,777,000 | $46,046,000 | $19,069,000 | $14,323,000 |
| Net PPE | $5,510,000 | $2,994,000 | $3,900,000 | $4,602,000 |
| Accumulated Depreciation | $-3,248,000 | $-2,564,000 | $-1,924,000 | $-1,153,000 |
| Gross PPE | $8,758,000 | $5,558,000 | $5,824,000 | $5,755,000 |
| Leases | $1,568,000 | $1,568,000 | $1,568,000 | $1,568,000 |
| Other Properties | $4,467,000 | $1,953,000 | $2,361,000 | $2,721,000 |
| Machinery Furniture Equipment | $2,723,000 | $2,037,000 | $1,895,000 | $1,466,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $12,554,000 | $9,642,000 | $2,697,000 | $1,460,000 |
| Work In Process | $5,033,000 | $584,000 | $486,000 | $395,000 |
| Raw Materials | $5,047,000 | $4,300,000 | $9,951,000 | $5,659,000 |
| Other Short Term Investments | $178,075,000 | $156,620,000 | $183,463,000 | $355,948,000 |
| Preferred Stock | - | $0 | $0 | $0 |
| Current Capital Lease Obligation | - | $820,000 | $735,000 | $657,000 |
| Construction In Progress | - | - | - | - |
Fetched: 2026-06-09
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-16,311,000 | $-117,301,000 | $-247,485,000 | $-280,998,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-5,625,000 | $-112,158,000 | $-247,057,000 | $-257,715,000 |
| Cash Flow From Continuing Operating Activities | $-5,625,000 | $-112,158,000 | $-247,057,000 | $-257,715,000 |
| Operating Gains Losses | - | $-279,000 | $849,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-10,686,000 | $-5,143,000 | $-428,000 | $-23,283,000 |
| Investing Cash Flow | $-30,253,000 | $28,820,000 | $180,232,000 | $-87,199,000 |
| Cash Flow From Continuing Investing Activities | $-30,253,000 | $28,820,000 | $180,232,000 | $-87,199,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $161,682,000 | $98,901,000 | $176,047,000 |
| Financing Cash Flow | $6,973,000 | $66,202,000 | $101,323,000 | $301,798,000 |
| Cash Flow From Continuing Financing Activities | $6,973,000 | $66,202,000 | $101,323,000 | $301,798,000 |
| Net Common Stock Issuance | $0 | $161,682,000 | $98,901,000 | $176,047,000 |
| Common Stock Issuance | $0 | $161,682,000 | $98,901,000 | $176,047,000 |
| Net Other Financing Charges | - | - | - | $-2,187,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $0 | $-100,000,000 | $0 | $0 |
| Interest Paid Supplemental Data | $10,327,000 | $22,209,000 | $25,445,000 | $12,636,000 |
| End Cash Position | $43,215,000 | $71,952,000 | $89,323,000 | $54,875,000 |
| Beginning Cash Position | $71,952,000 | $89,323,000 | $54,875,000 | $97,991,000 |
| Effect Of Exchange Rate Changes | $168,000 | $-235,000 | $-50,000 | $0 |
| Changes In Cash | $-28,905,000 | $-17,136,000 | $34,498,000 | $-43,116,000 |
| Proceeds From Stock Option Exercised | $6,973,000 | $4,520,000 | $2,422,000 | $2,938,000 |
| Net Issuance Payments Of Debt | $0 | $-100,000,000 | $0 | $125,000,000 |
| Net Long Term Debt Issuance | $0 | $-100,000,000 | $0 | $125,000,000 |
| Long Term Debt Payments | $0 | $-100,000,000 | $0 | $0 |
| Net Investment Purchase And Sale | $-19,567,000 | $33,963,000 | $180,660,000 | $-63,916,000 |
| Sale Of Investment | $227,419,000 | $288,783,000 | $406,500,000 | $351,473,000 |
| Purchase Of Investment | $-246,986,000 | $-254,820,000 | $-225,840,000 | $-415,389,000 |
| Net Intangibles Purchase And Sale | $-10,000,000 | $-5,000,000 | $0 | $-22,950,000 |
| Purchase Of Intangibles | $-10,000,000 | $-5,000,000 | $0 | $-22,950,000 |
| Net PPE Purchase And Sale | $-686,000 | $-143,000 | $-428,000 | $-333,000 |
| Purchase Of PPE | $-686,000 | $-143,000 | $-428,000 | $-333,000 |
| Change In Working Capital | $-34,829,000 | $-15,080,000 | $-23,501,000 | $-10,175,000 |
| Change In Other Current Liabilities | $-680,000 | $-735,000 | $-657,000 | $-433,000 |
| Change In Payables And Accrued Expense | $48,350,000 | $34,262,000 | $8,746,000 | $2,758,000 |
| Change In Accrued Expense | $50,044,000 | $32,033,000 | $5,594,000 | $1,193,000 |
| Change In Payable | $-1,694,000 | $2,229,000 | $3,152,000 | $1,565,000 |
| Change In Account Payable | $-1,694,000 | $2,229,000 | $3,152,000 | $1,565,000 |
| Change In Prepaid Assets | $-2,007,000 | $-948,000 | $-8,621,000 | $3,472,000 |
| Change In Inventory | $-7,329,000 | $-400,000 | $-5,620,000 | $-7,514,000 |
| Change In Receivables | $-73,163,000 | $-47,259,000 | $-17,349,000 | $-8,458,000 |
| Changes In Account Receivables | $-73,163,000 | $-47,259,000 | $-17,349,000 | $-8,458,000 |
| Other Non Cash Items | $2,408,000 | $6,173,000 | $6,010,000 | $32,555,000 |
| Stock Based Compensation | $40,364,000 | $41,730,000 | $38,813,000 | $32,682,000 |
| Amortization Of Securities | $-2,094,000 | $-6,901,000 | $-6,989,000 | $-2,253,000 |
| Depreciation Amortization Depletion | $4,667,000 | $1,959,000 | $750,000 | $934,000 |
| Depreciation And Amortization | $4,667,000 | $1,959,000 | $750,000 | $934,000 |
| Amortization Cash Flow | $4,667,000 | $1,959,000 | $750,000 | $312,000 |
| Amortization Of Intangibles | $4,667,000 | $1,959,000 | $750,000 | $312,000 |
| Net Income From Continuing Operations | $-16,141,000 | $-140,039,000 | $-262,140,000 | $-311,458,000 |
| Issuance Of Debt | - | $0 | $0 | $125,000,000 |
| Long Term Debt Issuance | - | $0 | $0 | $125,000,000 |
| Depreciation | - | $640,000 | $771,000 | $622,000 |
| Gain Loss On Investment Securities | - | $-279,000 | $849,000 | - |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
Fetched: 2026-06-09